Q 1802
Alternative Names: Q-1802Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator QureBio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Claudin 18 protein inhibitors; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Gastric cancer; Solid tumours
Most Recent Events
- 06 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV)
- 06 Nov 2024 Efficacy and adverse events data from a phase II trial in Solid tumours released by QureBio
- 21 Jun 2023 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, First-line therapy) in China (IV) (NCT05964543)